NEO stock forecast
Our latest prediction for NeoGenomics, Inc.'s stock price was made on the Nov. 19, 2019 when the stock price was at 24.22$.
In the short term (2weeks), NEO's stock price should outperform the market by 0.20%. During that period the price should oscillate between -5.94% and +5.83%.
In the medium term (3months), NEO's stock price should outperform the market by 1.83%. During that period the price should oscillate between -14.40% and +17.93%.Get email alerts
About NeoGenomics, Inc.
NeoGenomics, Inc. is a clinical laboratory, which specializes in cancer genetics diagnostic testing and pharma services. It operates through the following two segments: Clinical and Pharma Services. The Clinical Services segment offers clinical cancer testing services to community-based pathologists. The Pharma Services segments supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. The Clinical Services Segment provides various clinical testing services to community-based pathology practices, hospital pathology labs and academic centers with reimbursement from various payers including client direct billing, commercial insurance, Medicare and other government payers, and patients. The Pharma Services segment: provides comprehensive testing services in supports pharmaceutical clients' oncology programs from discovery to commercialization. Its services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry, anatomic pathology and molecular genetic testing. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.
At the moment the company generates 378M USD in revenues.
On its last earning announcement, the company reported a profit of 0.02$ per share.
The book value per share is 2.00$
Three months stock forecastNov. 19, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|